Status: Recruiting
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
The purpose of this study is to improve upon the TINI study treatment. The study will test the ability of a type of immunotherapy called blinatumomab to clear persistent leukemia. Blinatumomab targets CD19 which is located on the leukemia cells outer membrane.
Participants needed: 90
Trial details
Phase: Phase 1, Phase 2Age: Up to 1Biological sex: AllType: InterventionalSponsor: Tanja Andrea GruberUpdated: Jun 3, 2026Locations: 24
Eligibility criteria
Patient is ≤ 365 days of age at the time of diagnosis. [+3]
Patients with prior therapy, other than therapy specified in inclusion criteria. [+3]